Profile: Orthofix International NV (OFIX.O)
29 Jan 2015
Orthofix International N.V. (Orthofix), incorporated on October 19, 1987, is a diversified medical device company focused on developing and delivering repair and regenerative solutions to the spine and orthopedic markets. The Company designs, develops, manufactures, markets and distributes medical devices used principally by musculoskeletal medical specialists for spine and orthopedic applications. Its main products are spinal implant products human cellular and tissue based products (HCT/P products) used in surgical procedures, non-invasive regenerative stimulation products used to enhance bone growth and the success rate of spinal fusions and to treat non-union fractures, and external and internal fixation devices used in fracture repair, limb lengthening and bone reconstruction. In addition, the Company offers bone cement and devices for removal of bone cement used to fix artificial implants. The Company directly distributes its products in the United States, the United Kingdom, Italy, Germany, France, Belgium, Brazil, Australia, and Puerto Rico. In several other markets, Orthofix distributes its products through independent distributors. The Company manages its business through four strategic business units (SBUs), which are comprised of BioStim, Biologics, Extremity Fixation and Spine Fixation.
The BioStim SBU manufactures, distributes, and provides support services for a portfolio of devices for enhancing bone fusion that utilize Orthofix’s pulsed electromagnetic (PEMF) technology. These Food and Drug Administration-approved Class 3 medical devices are indicated as an adjunctive treatment to enhance fusion success in cervical and lumbar spine fusion as well as a therapeutic treatment for non-healing fractures outside of the spine (non-unions).
The Biologics SBU provides a portfolio of regenerative products that allow physicians to treat a variety of spinal and orthopedic conditions. This SBU specializes in the marketing of the Company’s regeneration tissue forms. The Biologics SBU distributes its tissues through a network of distributors, sales, representatives and affiliates to market to hospitals, doctors, and other healthcare providers, primarily in the United States. The Company’s partnership with MTF allows it to exclusively market Trinity Evolution and Trinity Elite tissue forms for musculoskeletal defects to enhance bone fusion.
The Extremity Fixation SBU offers products that allow physicians to treat a variety of orthopedic conditions unrelated to the spine. This SBU specializes in the design, development, and marketing of the Company’s orthopedic products used in fracture repair, deformity correction and bone reconstruction. Extremity Fixation distributes its products through a network of distributors, sales representatives, and affiliates. This SBU uses both distributors and direct sales representatives to sell orthopedics products to hospitals, doctors, and other health providers, globally.
The Spine Fixation SBU specializes in the design, development and marketing of a portfolio of implant products used in surgical procedures of the spine. Spine Fixation distributes its products through a network of distributors and affiliates. This SBU uses distributors and direct sales representatives to sell spine products to hospitals, doctors and other healthcare providers, globally. The Company competes with Biomet Spine, a business unit of Biomet, Inc.; DJO Incorporated; the Exogen product line owned by Smith; Nephew plc; Essex Woodland, a private equity firm; Medtronic, Inc.; De Puy Synthes, a division of Johnson and Johnson; Stryker Corp.; Zimmer, Inc.; NuVasive; Biomet Spine; Smith & Nephew plc; and Biomet Orthopedics, a business unit of Biomet, Inc.
Orthofix International NV
7 Abraham de Veerstraat